Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting

被引:13
|
作者
Townsend, Jeffrey P. [1 ,2 ,3 ,4 ,6 ]
Hassler, Hayley B. [1 ]
Dornburg, Alex [5 ]
机构
[1] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[2] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT USA
[3] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA
[4] Yale Univ, Program Microbiol, New Haven, CT USA
[5] Univ N Carolina, Dept Bioinformat & Genom, Charlotte, NC USA
[6] Yale Sch Publ Hlth, Dept Biostat, 135 Coll St, New Haven, CT 06510 USA
基金
美国国家科学基金会;
关键词
BNT162b2; mRNA-1273; mRNA vaccines; SARS-CoV-2 variant evolution; updated COVID-19 vaccine; vaccination schedule; ANTIBODY-RESPONSES; DURATION; COVID-19;
D O I
10.1002/jmv.28461
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
One of the most consequential unknowns of the COVID-19 pandemic is the frequency at which vaccine boosting provides sufficient protection from infection. We quantified the statistical likelihood of breakthrough infections over time following different boosting schedules with messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). We integrated anti-Spike IgG antibody optical densities with profiles of the waning of antibodies and corresponding probabilities of infection associated with coronavirus endemic transmission. Projecting antibody levels over time given boosting every 6 months, 1, 1.5, 2, or 3 years yielded respective probabilities of fending off infection over a 6-year span of >93%, 75%, 55%, 40%, and 24% (mRNA-1273) and >89%, 69%, 49%, 36%, and 23% (BNT162b2). Delaying the administration of updated boosters has bleak repercussions. It increases the probability of individual infection by SARS-CoV-2, and correspondingly, ongoing disease spread, prevalence, morbidity, hospitalization, and mortality. Instituting regular, population-wide booster vaccination updated to predominant variants has the potential to substantially forestall-and with global, widespread uptake, eliminate-COVID-19.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Infection with alternate frequencies of SARS-CoV-2 vaccine boosting for patients undergoing antineoplastic cancer treatments
    Townsend, Jeffrey P.
    Hassler, Hayley B.
    Emu, Brinda
    Dornburg, Alex
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (12): : 1626 - 1628
  • [2] HLA FREQUENCIES IN SARS-COV-2 INFECTION
    Xochelli, Aliki
    Papadopoulou, Anastasia
    Tsinaris, Zafeiris
    Lioulios, Georgios
    Anastasiou, Katerina
    Boukla, Anna
    Makrobasili, Fani
    Chatzika, Georgia
    Gioula, Georgia
    Yannaki, Evangelia
    Fylaktou, Asimina
    HLA, 2021, 97 (04) : 312 - 312
  • [3] Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection
    Roberto Stellini
    Renzo Gianello
    Angelo Meloni
    Elia Croce
    Paola Materzanini
    Walter Gomarasca
    Infection, 2022, 50 : 791 - 793
  • [4] Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection
    Stellini, Roberto
    Gianello, Renzo
    Meloni, Angelo
    Croce, Elia
    Materzanini, Paola
    Gomarasca, Walter
    INFECTION, 2022, 50 (03) : 791 - 793
  • [5] A SARS-CoV-2 mRNA Vaccine - Preliminary Report
    Jackson, Lisa A.
    Roberts, Paul C.
    Graham, Barney S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12): : 1190 - 1192
  • [6] Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine)
    Daldoul, M.
    Korbi, M.
    Bellalah, A.
    Ben Fadhel, N.
    Belhadjali, H.
    Zili, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : E743 - E744
  • [7] Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
    Abu-Raddad, L. J.
    Chemaitelly, H.
    Ayoub, H. H.
    AlMukdad, S.
    Yassine, H. M.
    Al-Khatib, H. A.
    Smatti, M. K.
    Tang, P.
    Hasan, M. R.
    Coyle, P.
    Al-Kanaani, Z.
    Al-Kuwari, E.
    Jeremijenko, A.
    Kaleeckal, A. H.
    Latif, A. N.
    Shaik, R. M.
    Abdul-Rahim, H. F.
    Nasrallah, G. K.
    Al-Kuwari, M. G.
    Butt, A. A.
    Al-Romaihi, H. E.
    Al-Thani, M. H.
    Al-Khal, A.
    Bertollini, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (19): : 1804 - 1816
  • [8] Symptomatic SARS-CoV-2 Infection with Ageusia after Two mRNA Vaccine Doses
    Caponio, Vito Carlo Alberto
    Lipsi, Maria Rosaria
    Fortunato, Francesca
    Arena, Fabio
    Lo Muzio, Lorenzo
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (02)
  • [9] Bioinformatics Designing and Molecular Modelling of a Universal mRNA Vaccine for SARS-CoV-2 Infection
    Oladipo, Elijah Kolawole
    Adeniyi, Micheal Oluwafemi
    Ogunlowo, Mercy Temiloluwa
    Irewolede, Boluwatife Ayobami
    Adekanola, Victoria Oluwapelumi
    Oluseyi, Glory Samuel
    Omilola, Janet Abisola
    Udoh, Anietie Femi
    Olufemi, Seun Elijah
    Adediran, Daniel Adewole
    Olonade, Aanuoluwapo
    Idowu, Usman Abiodun
    Kolawole, Olatunji M.
    Oloke, Julius Kola
    Onyeaka, Helen
    VACCINES, 2022, 10 (12)
  • [10] SARS-CoV-2 mRNA vaccine injection site pseudolymphoma
    Mintoff, D.
    Scerri, L.
    Betts, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (01) : 23 - E22